Bioventus Inc.
About Bioventus Inc.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $568.1M
- Net income
- $22.7M
- Total assets
- $683.6M
- Market cap
- $612.4M
- Gross margin
- 68.3%
- Operating margin
- 9.5%
- Net margin
- 4.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $568.1M
- Cost of revenue
- $179.9M
- Gross profit
- $388.2M
- Operating expenses
- $334.2M
- Operating income
- $54.0M
- Income tax
- -$1.6M
- Net income
- $27.3M
- EPS (basic)
- $0.34
- EPS (diluted)
- $0.33
Balance sheet
- Total assets
- $683.6M
- Current assets
- $272.8M
- Total liabilities
- $455.1M
- Current liabilities
- $160.4M
- Shareholders’ equity
- $228.4M
Cash flow
- Operating cash flow
- $74.7M
- Investing cash flow
- -$3.2M
- Financing cash flow
- -$62.1M
- Net cash flow
- $9.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $612.4M
- P/E ratio
- 27.4
- EPS (diluted)
- $0.33
- Shares outstanding
- 67.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 11, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $22.7M in FY2025.
- Revenue grew 32% from FY2021 to FY2025.
- Gross margin of 68.3%, net margin 4.8%.
- Trading 17% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 27.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bioventus Inc..
Write a review
News about Bioventus Inc.
News & sentiment via Polygon.io
